Rakhi Naik MD, MHSAssociate Director for Hematology, Hematology/Oncology Fellowship Program; Associate Professor of Medicine, Hematology, Johns Hopkins Medicine, Baltimore, Maryland
Dr. Naik graduated from Duke University with a degree in Biomedical and Electrical Engineering and received her MD from Cornell Medical School. She also holds a Masters in Health Sciences (MHS) from the Johns Hopkins Bloomberg School of Public Health. Dr. Naik has been at Hopkins since 2006, serving as Osler residency housestaff, hematology fellow, and Assistant Chief of Service (Chief Resident) prior to being recruited to faculty as an Assistant Professor in May 2013. She currently serves as the Associate Director for Hematology for the Hematology-Oncology Fellowship Program and is an Associate Professor of Medicine at Johns Hopkins Medicine.
Dr. Naik’s primary research involves the genetic epidemiology of sickle hemoglobin disorders, with the goal of informing genetic counseling, screening and treatment guidelines. She is currently involved in several large-scale epidemiologic efforts using National Heart, Lung, and Blood Institute (NHLBI) population study cohorts to define clinical complications of sickle cell trait, including venous thromboembolism, renal disease, cardiovascular disease, and stroke.
Dr. Naik serves on the American Society of Hematology (ASH) Committee on Training and is a member of the ASH Recruitment and Retention Working Group, which aims to increase the recruitment of trainees into benign hematology.
Recent Contributions to PracticeUpdate:
- Safety and Efficacy of Mitapivat in Sickle Cell Disease
- 2021 Top Story in Benign Hematology: Building on Data for Voxelotor in Sickle Cell Disease
- Comorbidities Are Risk Factors for Hospitalization and Serious COVID-19 Illness in Patients With Sickle Cell Disease
- Eliminating Race-Based Reference Ranges in Haematology
- Quality of Life in Sickle Cell Disease and Thalassemia After Stem Cell Transplant or Gene Therapy
- 2020 Top Stories in Benign Hematology: A New Treatment for a Rare Disease: Givosiran for the Acute Hepatic Porphyrias
- Management of Acute and Chronic Pain in Sickle Cell Disease
- Coagulopathy and Antiphospholipid Antibodies in Patients With COVID-19
- Prevalence of VTE in Patients With Severe Novel Coronavirus Pneumonia
- COVID-19: Through a Hematologic Filter